PKA/CREB regulates the constitutive promoter activity of the USP22 gene

Oncology Reports

Volumn 33, Issue 3, 2015, Pages 1505-1511

  Xiong, Jianjun ^a   Zhou, Xiaoou ^a   Gong, Zhen ^a   Wang, Ting ^a   Zhang, Chao ^b   Xu, Xiaoyuan ^a   Liu, Jianyun ^a   Li, Weidong ^a  

^a JIUJIANG UNIVERSITY   (China)

^b Maternal and Child Health Hospital of Jiujiang City   (China)

Author keywords

CREB; PKA; Promoter; USP22

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR; CASPASE ACTIVATED DEOXYRIBONUCLEASE; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLIN D2; DNA; FORSKOLIN; HISTONE DEACETYLASE; MYC PROTEIN; SMALL INTERFERING RNA; UBIQUITIN SPECIFIC PROCESSING ENZYME 22; UNCLASSIFIED DRUG; CREB1 PROTEIN, HUMAN; ISOQUINOLINE DERIVATIVE; N-(2-(4-BROMOCINNAMYLAMINO)ETHYL)-5-ISOQUINOLINESULFONAMIDE; PROTEIN KINASE INHIBITOR; SULFONAMIDE; THIOL ESTER HYDROLASE; USP22 PROTEIN, HUMAN;

ARTICLE; BINDING SITE; CANCER CELL; CARCINOGENESIS; CELL CYCLE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA FLANKING REGION; DNA SEQUENCE; GENE; GENE EXPRESSION; HELA CELL LINE; HEPG2 CELL LINE; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PROMOTER REGION; PROTEIN STRUCTURE; TRANSCRIPTION INITIATION; TUMOR GROWTH; USP22 GENE; UTERINE CERVIX CARCINOMA; BIOSYNTHESIS; GENETICS; METABOLISM; MUTATION; NEOPLASM; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE;

BINDING SITES; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; COLFORSIN; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; HELA CELLS; HEP G2 CELLS; HUMANS; ISOQUINOLINES; MUTATION; NEOPLASMS; PROMOTER REGIONS, GENETIC; PROTEIN KINASE INHIBITORS; RNA INTERFERENCE; RNA, SMALL INTERFERING; SULFONAMIDES; THIOLESTER HYDROLASES; TRANSCRIPTIONAL ACTIVATION;

EID: 84921683841     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.3740     Document Type: Article

References (31)

1. Lee HJ, Kim MS, Shin JM, Park TJ, Chung HM and Baek KH: The expression patterns of deubiquitinating enzymes, USP22 and Usp22. Gene Expr Patterns 6:277-284, 2006.
2. Liu Y, Yang Y, Xu H and Dong X: Implication of USP22 in the regulation of BMI-1, c-Myc, p16INK4a, p14ARF, and cyclin D2 expression in primary colorectal carcinomas. Diagn Mol Pathol 19:194-200, 2010.
3. Yang DD, Cui BB, Sun LY, et al: The co-expression of USP22 and BMI-1 may promote cancer progression and predict therapy failure in gastric carcinoma. Cell Biochem Biophys 61:703-710, 2011.
4. Zhang Y, Yao L, Zhang X, et al: Elevated expression of USP22 in correlation with poor prognosis in patients with invasive breast cancer. J Cancer Res Clin Oncol 137:1245-1253, 2011.
5. Zhang XY, Varthi M, Sykes SM, et al: The putative cancer stem cell marker USP22 is a subunit of the human SAGA complex required for activated transcription and cell-cycle progression. Mol Cell 29:102-111, 2008.
6. Zhao Y, Lang G, Ito S, et al: A TFTC/STAGA module mediates histone H2A and H2B deubiquitination, coactivates nuclear receptors, and counteracts heterochromatin silencing. Mol Cell 29:92-101, 2008.
7. Atanassov BS, Evrard YA, Multani AS, et al: Gcn5 and SAGA regulate shelterin protein turnover and telomere maintenance. Mol Cell 35:352-364, 2009.
8. Lin Z, Yang H, Kong Q, et al: USP22 antagonizes p53 transcriptional activation by deubiquitinating Sirt1 to suppress cell apoptosis and is required for mouse embryonic development. Mol Cell 46:484-494, 2012.
9. Atanassov BS and Dent SY: USP22 regulates cell proliferation by deubiquitinating the transcriptional regulator FBP1. EMBO Rep 12:924-930, 2011.
10. Sussman RT, Stanek TJ, Esteso P, Gearhart JD, Knudsen KE and McMahon SB: The epigenetic modifier ubiquitin-specific protease 22 (USP22) regulates embryonic stem cell differentiation via transcriptional repression of sex-determining region Y-box 2 (SOX2). J Biol Chem 288:24234-24246, 2013.
11. Xiong J, Che X, Li X, Yu H, Gong Z and Li W: Cloning and characterization of the human USP22 gene promoter. PLoS One 7:e52716, 2012.
12. Bubis M and Zisapel N: Modulation by melatonin of protein secretion from melanoma cells: is cAMP involved? Mol Cell Endocrinol 112:169-175, 1995.
13. Nakamura K, Bossy-Wetzel E, Burns K, et al: Changes in endoplasmic reticulum luminal environment affect cell sensitivity to apoptosis. J Cell Biol 150:731-740, 2000.
14. Zong Y, Sun L, Liu B, et al: Resveratrol inhibits LPS-induced MAPK activation via activation of the phosphatidylinositol 3-kinase pathway in murine RAW 264.7 macrophage cells. PLoS One 7:e44107, 2012.
15. Glinsky GV: Death-from-cancer signatures and stem cell contribution to metastatic cancer. Cell Cycle 4:1171-1175, 2005.
16. Glinsky GV: Genomic models of metastatic cancer: functional analysis of death-from-cancer signature genes reveals aneuploid, anoikis-resistant, metastasis-enabling phenotype with altered cell cycle control and activated Polycomb Group (PcG) protein chromatin silencing pathway. Cell Cycle 5:1208-1216, 2006.
17. Tinti C, Yang C, Seo H, et al: Structure/function relationship of the cAMP response element in tyrosine hydroxylase gene transcription. J Biol Chem 272:19158-19164, 1997.
18. Euskirchen G and Snyder M: A plethora of sites. Nat Genet 36:325-326, 2004.
19. White PC, Shore AM, Clement M, et al: Regulation of cyclin D2 and the cyclin D2 promoter by protein kinase A and CREB in lymphocytes. Oncogene 25:2170-2180, 2006.
20. Wilson BE, Mochon E and Boxer LM: Induction of bcl-2 expression by phosphorylated CREB proteins during B-cell activation and rescue from apoptosis. Mol Cell Biol 16:5546-5556, 1996.
21. Mayer SI, Willars GB, Nishida E and Thiel G: Elk-1, CREB, and MKP-1 regulate Egr-1 expression in gonadotropin-releasing hormone stimulated gonadotrophs. J Cell Biochem 105:1267-1278, 2008.
22. Sakamoto KM and Frank DA: CREB in the pathophysiology of cancer: implications for targeting transcription factors for cancer therapy. Clin Cancer Res 15:2583-2587, 2009.
23. Melnikova VO, Dobroff AS, Zigler M, et al: CREB inhibits AP-2alpha expression to regulate the malignant phenotype of melanoma. PLoS One 5:e12452, 2010.
24. Quinn PG: Distinct activation domains within cAMP response element-binding protein (CREB) mediate basal and cAMP-stimulated transcription. J Biol Chem 268:16999-17009, 1993.
25. Rosenberg D, Groussin L, Jullian E, Perlemoine K, Bertagna X and Bertherat J: Role of the PKA-regulated transcription factor CREB in development and tumorigenesis of endocrine tissues. Ann NY Acad Sci 968:65-74, 2002.
26. Guo Y and Feng P: OX2R activation induces PKC-mediated ERK and CREB phosphorylation. Exp Cell Res 318:2004-2013, 2012.
27. Takeda H, Kitaoka Y, Hayashi Y, et al: Calcium/calmodulindependent protein kinase II regulates the phosphorylation of CREB in NMDA-induced retinal neurotoxicity. Brain Res 1184:306-315, 2007.
28. Gibellini D, Bassini A, Pierpaoli S, et al: Extracellular HIV-1 Tat protein induces the rapid Ser133 phosphorylation and activation of CREB transcription factor in both Jurkat lymphoblastoid T cells and primary peripheral blood mononuclear cells. J Immunol 160:3891-3898, 1998.
29. Delghandi MP, Johannessen M and Moens U: The cAMP signalling pathway activates CREB through PKA, p38 and MSK1 in NIH 3T3 cells. Cell Signal 17:1343-1351, 2005.
30. Atlas E, Stramwasser M and Mueller CR: A CREB site in the BRCA1 proximal promoter acts as a constitutive transcriptional element. Oncogene 20:7110-7114, 2001.
31. Conkright MD, Guzman E, Flechner L, Su AI, Hogenesch JB and Montminy M: Genome-wide analysis of CREB target genes reveals a core promoter requirement for cAMP responsiveness. Mol Cell 11:1101-1108, 2003.